What are the current recommendations for high‑risk human papillomavirus (HPV) testing in cervical cancer screening, including age‑specific intervals, management of positive results, and considerations for pregnancy, men, and vaccination?

HPV Testing for Cervical Cancer Screening

For average-risk women aged 30-65 years, cotesting with cytology plus HPV testing every 5 years is the preferred screening strategy, while primary HPV testing alone every 5 years is emerging as the preferred approach according to the most recent 2020 American Cancer Society guidelines. 1, 2

Age-Specific HPV Testing Recommendations

Women Under Age 21

• Do not perform any cervical cancer screening, including HPV testing, regardless of sexual history or age at first intercourse 3, 1
• Screening before age 21 causes more harm than benefit due to high rates of transient HPV infections and unnecessary treatment of lesions that would naturally regress 1, 4

Women Ages 21-29 Years

• HPV testing is not recommended for primary screening in this age group, either alone or as cotesting with cytology 3, 1
• Screen with cytology alone every 3 years 3, 1
• HPV testing may be used only for triage of ASC-US results in women aged 25-29 years, but this is not routine screening 3, 1
• Rationale: HPV prevalence is extremely high (often >30%) in this age group, but most infections clear spontaneously within 2 years, making HPV testing lead to excessive false-positives and overtreatment 1, 5

Women Ages 30-65 Years (Standard Risk)

Three acceptable screening options exist, with evolving preferences:

1. Cotesting (HPV + cytology) every 5 years – preferred by NCCN and ACOG 3, 1, 4
2. Primary HPV testing alone every 5 years – preferred by the 2020 American Cancer Society guideline 1, 2
3. Cytology alone every 3 years – acceptable but less preferred 3, 1

• A negative cotest (HPV-negative and cytology-negative) confers the lowest 5-year risk of CIN 2+ at only 0.27%, justifying the 5-year interval 3
• The U.S. is transitioning toward primary HPV testing as the standard, with cotesting and cytology-alone expected to be phased out in future guidelines 1, 2

Management of Positive HPV Test Results

HPV-Positive with Negative Cytology

• Repeat cotesting in 6-12 months (not immediate colposcopy) 3
• This result carries approximately 10% risk of HSIL/cancer over 5 years 3
• If either test is abnormal at follow-up, proceed to colposcopy 6

HPV-Positive with Abnormal Cytology

Immediate colposcopy is indicated for:

• HPV-positive with HSIL (71% risk of HSIL/cancer) 3
• HPV-positive with ASC-H (45% risk) 3
• HPV-positive with LSIL (19% risk) 3
• HPV-positive with ASC-US (18% risk) 3
• HPV-positive with AGC (45% risk) 3

HPV-Negative with Abnormal Cytology

• HPV-negative with ASC-US: Repeat testing in 3 years (only 1.1% risk) 3
• HPV-negative with LSIL: Repeat testing in 6-12 months (5.1% risk) 3
• HPV-negative with HSIL or AGC: Immediate colposcopy despite negative HPV (12-49% risk) 3

Discontinuing Screening After Age 65

Stop all cervical cancer screening when ALL three criteria are met:

1. Adequate prior screening: either 3 consecutive negative cytology tests OR 2 consecutive negative cotests within the past 10 years 3, 1
2. Most recent test performed within the past 5 years 3, 1
3. No history of CIN 2/3, adenocarcinoma in situ, or cervical cancer 3, 1

Continue screening beyond age 65 if:

• History of CIN 2/3 or cervical cancer (continue for 20-25 years after treatment) 1, 4
• HIV infection or immunosuppression 1, 4
• In-utero diethylstilbestrol (DES) exposure 1, 4
• Inadequate prior screening history 1

Special Populations

Pregnancy

• Follow the same age-based screening intervals as non-pregnant women 4
• For pregnant women with LSIL, colposcopy is preferred but may be deferred until 6 weeks postpartum 3, 4
• Do not treat CIN 1 during pregnancy 3, 4
• CIN 3 can wait until after delivery for treatment 3
• Endocervical curettage is contraindicated in pregnancy 3

Post-Hysterectomy

• Discontinue all screening after total hysterectomy with cervix removal if no history of CIN 2/3 or cervical cancer in the past 25 years 3, 1, 4
• Continue screening if subtotal hysterectomy (cervix retained) or history of high-grade lesions 3, 1

Immunocompromised Women

• HIV-positive women require more intensive, often annual screening 1, 4
• Organ transplant recipients, chronic corticosteroid users, and chemotherapy patients need individualized intensified surveillance 1, 4

Transgender Men with a Cervix

• Follow identical screening recommendations as cisgender women 1
• Testosterone therapy does not alter screening guidelines 1
• Screen every 3-5 years at ages 30-65 using the same HPV testing strategies 1

HPV Vaccination Considerations

Vaccinated women follow the exact same screening recommendations as unvaccinated women 3, 1, 2, 4

• Current HPV vaccines cover approximately 70% of oncogenic HPV types (primarily types 16 and 18) but do not protect against all high-risk types 1, 4
• Vaccination does not eliminate the need for routine screening 3, 1, 2
• Cytology-based screening becomes less efficient in vaccinated populations, further supporting the transition to primary HPV testing 2

Common Pitfalls to Avoid

• Never screen women under age 21 with HPV testing or cytology, regardless of sexual history 1, 4
• Never perform annual screening in any age group—it provides no additional benefit and increases harms through unnecessary procedures 3, 1, 4
• Never use HPV testing for primary screening in women under 30—the high prevalence of transient infections leads to excessive false-positives and overtreatment 3, 1
• Never resume screening after age 65 in women who met adequate prior screening criteria, even with a new sexual partner 4
• Do not immediately colposcopy HPV-positive/cytology-negative results—repeat testing in 6-12 months is appropriate 3, 6

Emerging Evidence

Recent research demonstrates that primary HPV testing in women aged 25-30 years detects significantly more CIN 3+ lesions than cytology (OR 1.4, p<0.001), though at the cost of higher colposcopy referral rates (9.8% vs 7.8%) 5. This supports the 2020 ACS recommendation to begin primary HPV testing at age 25, though this represents a departure from older guidelines that recommended cytology alone until age 30 1, 2.